RESUMEN
When NA808, a potent HCV replication inhibitor, was intravenously administered to rats, it was distributed to the liver. The AUC ratio in the liver of 20 mg/kg to 2 mg/kg was greater than the dose ratio, whereas exposure in plasma was increased in a dose-proportional manner. Saturation of biliary excretion was also shown at 20 mg/kg.NA808 was revealed to be a substrate for both OATP1B and MRP2 transporters by an in vitro study using OATP1B1-MRP2 expressing cells. [14C]NA808 was taken up into the cells by OATP1B1 and excreted from cells by MRP2 efficiently (Papp ratio: 24.2-70.2). The Papp ratio decreased with increasing NA808 concentration.PBPK modelling was constructed to display the blood and liver concentration time profile and biliary excretion of NA808. This model analysis was able to reproduce the pharmacokinetics in rats; the degree of increase in the liver exposure from 2 to 20 mg/kg was more than dose-proportional and was greater than the increase in the blood exposure due to saturation of efflux transporters.In drug development, to avoid unexpected toxicity in tissues, it is important to consider the potential for tissue non-linearity with linear plasma exposure based on pre-clinical data and PBPK modelling.
Asunto(s)
Citratos , Hígado , Ratas , Animales , Hígado/metabolismo , Citratos/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Transporte BiológicoRESUMEN
Large amounts of monocyclic aromatic hydrocarbons (MAHs) are emitted into the atmosphere, but it is unclear which compounds among MAHs are effectively removed by the above-ground parts of plants. Although fumigation experiments of MAHs at unrealistically high concentrations (~ppmv) have been conducted, experiments with ambient concentrations have scarcely been conducted. In the present study, MAHs, including benzene, toluene, phenol, benzaldehyde, and benzyl alcohol, with concentrations ranging from several to several tens ppbv, were individually fumigated to four plant species, and the uptake was monitored using proton-transfer-reaction mass spectrometry and gas chromatography-mass spectrometry. No detectable uptake was observed for benzene and toluene, but phenol, benzaldehyde, and benzyl alcohol were significantly taken up by the plants. The uptake rate normalized to fumigated concentration varied from 3 to 50 mmol m-2s-1 during the light period, depending on light intensity and compounds. The difference in uptake capability may be attributed not only to different metabolic activities but also to different values of Henry's law constant, which regulates the partitioning of these compounds into the liquid phase in leaves. The uptake of phenol, benzaldehyde, and benzyl alcohol was affected by stomatal conductance, suggesting that stomatal opening is the main factor regulating the uptake of the three MAHs. This is the first observation that anisole is emitted when phenol is fumigated to Spathiphyllum clevelandii, suggesting that phenol is methylated to anisole within plant leaves. Anisole is more volatile than phenol, meaning that methylation enhances the emission of xenobiotics into the atmosphere by converting them to more volatile compounds. This conversion ratio decreased with an increase in phenol concentration (from 1.3 to 143 ppbv). Considering low reaction rate coefficient of anisole with OH radicals and low conversion ratio from phenol to anisole, it is concluded that plants act to effectively remove oxygenated MAHs from the atmosphere.
Asunto(s)
Benceno , Hidrocarburos Aromáticos , Anisoles , Benzaldehídos , Benceno/análisis , Alcoholes Bencílicos , Fenoles , Hojas de la Planta/química , Plantas , Tolueno/análisisRESUMEN
UR-1102, a novel uricosuric agent for treating gout, has been confirmed to exhibit a pharmacological effect in patients. We clarified its metabolic pathway, estimated the contribution of each metabolic enzyme, and assessed the impact of genetic polymorphisms using human in vitro materials. Glucuronide, sulfate and oxidative metabolites of UR-1102 were detected in human hepatocytes. The intrinsic clearance by glucuronidation or oxidation in human liver microsomes was comparable, but sulfation in the cytosol was much lower, indicating that the rank order of contribution was glucuronidation ≥ oxidation > sulfation. Recombinant UGT1A1 and UGT1A3 showed high glucuronidation of UR-1102. We took advantage of a difference in the inhibitory sensitivity of atazanavir to the UGT isoforms and estimated the fraction metabolised (fm) with UGT1A1 to be 70%. Studies using recombinant CYPs and CYP isoform-specific inhibitors showed that oxidation was mediated exclusively by CYP2C9. The effect of UGT1A1 and CYP2C9 inhibitors on UR-1102 metabolism in hepatocytes did not differ markedly between the wild type and variants.
Asunto(s)
Citocromo P-450 CYP2C9/metabolismo , Glucuronosiltransferasa/metabolismo , Gota/tratamiento farmacológico , Oxazinas/uso terapéutico , Piridinas/uso terapéutico , Glucurónidos/metabolismo , Gota/metabolismo , Humanos , Microsomas Hepáticos/metabolismo , Oxazinas/metabolismo , Piridinas/metabolismoRESUMEN
Urate-lowering therapy is indispensable for the treatment of gout, but available drugs do not control serum urate levels tightly enough. Although the uricosurics benzbromarone and probenecid inhibit a urate reabsorption transporter known as renal urate transporter 1 (URAT1) and thus lower serum urate levels, they also inhibit other transporters responsible for secretion of urate into urine, which suggests that inhibiting URAT1 selectively would lower serum urate more effectively. We identified a novel potent and selective URAT1 inhibitor, UR-1102, and compared its efficacy with benzbromarone in vitro and in vivo. In human embryonic kidney (HEK)293 cells overexpressing URAT1, organic anion transporter 1 (OAT1), and OAT3, benzbromarone inhibited all transporters similarly, whereas UR-1102 inhibited URAT1 comparably to benzbromarone but inhibited OAT1 and OAT3 quite modestly. UR-1102 at 3-30 mg/kg or benzbromarone at 3-100 mg/kg was administered orally once a day for 3 consecutive days to tufted capuchin monkeys, whose low uricase activity causes a high plasma urate level. When compared with the same dosage of benzbromarone, UR-1102 showed a better pharmacokinetic profile, increased the fractional excretion of urinary uric acid, and reduced plasma uric acid more effectively. Moreover, the maximum efficacy of UR-1102 was twice that of benzbromarone, suggesting that selective inhibition of URAT1 is effective. Additionally UR-1102 showed lower in vitro potential for mechanisms causing the hepatotoxicity induced by benzbromarone. These results indicate that UR-1102 achieves strong uricosuric effects by selectively inhibiting URAT1 over OAT1 and OAT3 in monkeys, and could be a novel therapeutic option for patients with gout or hyperuricemia.
Asunto(s)
Benzbromarona/farmacología , Transportadores de Anión Orgánico/antagonistas & inhibidores , Proteínas de Transporte de Catión Orgánico/antagonistas & inhibidores , Oxazinas/farmacología , Piridinas/farmacología , Uricosúricos/farmacología , Animales , Cebus , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Relación Dosis-Respuesta a Droga , Femenino , Células HEK293 , Humanos , Masculino , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/metabolismo , Proteína 1 de Transporte de Anión Orgánico/biosíntesis , Proteína 1 de Transporte de Anión Orgánico/genética , Transportadores de Anión Orgánico/genética , Transportadores de Anión Orgánico Sodio-Independiente/biosíntesis , Transportadores de Anión Orgánico Sodio-Independiente/genética , Proteínas de Transporte de Catión Orgánico/genética , Unión Proteica , Ácido Úrico/sangre , Uricosúricos/efectos adversosRESUMEN
Abstract 1. The metabolism and drug-drug interaction (DDI) risk of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, were evaluated by in vitro studies using human liver microsomes, human hepatocytes, and recombinant human CYPs. 2. The main metabolite of tofogliflozin was the carboxylated derivative (M1) in human hepatocytes, which was the same as in vivo. The metabolic pathway of tofogliflozin to M1 was considered to be as follows: first, tofogliflozin was catalyzed to the primary hydroxylated derivative (M4) by CYP2C18, CYP4A11 and CYP4F3B, then M4 was oxidized to M1. 3. Tofogliflozin had no induction potential on CYP1A2 and CYP3A4. Neither tofogliflozin nor M1 had inhibition potential on CYPs, with the exception of a weak CYP2C19 inhibition by M1. 4. Not only are multiple metabolic enzymes involved in the tofogliflozin metabolism, but the drug is also excreted into urine after oral administration, indicating that tofogliflozin is eliminated through multiple pathways. Thus, the exposure of tofogliflozin would not be significantly altered by DDI caused by any co-administered drugs. Also, tofogliflozin seems not to cause significant DDI of co-administered drugs because tofogliflozin has no CYP induction or inhibition potency, and the main metabolite M1 has no clinically relevant CYP inhibition potency.
Asunto(s)
Compuestos de Bencidrilo/metabolismo , Glucósidos/metabolismo , Hepatocitos/metabolismo , Metabolómica/métodos , Microsomas Hepáticos/metabolismo , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Compuestos de Bencidrilo/química , Radioisótopos de Carbono , Coenzimas/metabolismo , Inhibidores Enzimáticos del Citocromo P-450/farmacología , Sistema Enzimático del Citocromo P-450/biosíntesis , Interacciones Farmacológicas , Inducción Enzimática/efectos de los fármacos , Glucósidos/química , Hepatocitos/efectos de los fármacos , Hepatocitos/enzimología , Humanos , Concentración 50 Inhibidora , Redes y Vías Metabólicas/efectos de los fármacos , Metaboloma/efectos de los fármacos , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Unión Proteica/efectos de los fármacos , Proteínas Recombinantes/metabolismo , Transportador 2 de Sodio-Glucosa/metabolismo , Factores de TiempoRESUMEN
Sodium-glucose cotransporter 2 (SGLT2) inhibitors showed a glucose lowering effect in type 2 diabetes patients through inducing renal glucose excretion. Detailed analysis of the mechanism of the glucosuric effect of SGLT2 inhibition, however, has been hampered by limitations of clinical study. Here, we investigated the mechanism of urinary glucose excretion using nonhuman primates with SGLT inhibitors tofogliflozin and phlorizin, both in vitro and in vivo. In cells overexpressing cynomolgus monkey SGLT2 (cSGLT2), both tofogliflozin and phlorizin competitively inhibited uptake of the substrate (α-methyl-d-glucopyranoside; AMG). Tofogliflozin was found to be a selective cSGLT2 inhibitor, inhibiting cSGLT2 more strongly than did phlorizin, with selectivity toward cSGLT2 1,000 times that toward cSGLT1; phlorizin was found to be a nonselective cSGLT1/2 inhibitor. In a glucose titration study in cynomolgus monkeys under conditions of controlled plasma drug concentration, both tofogliflozin and phlorizin increased fractional excretion of glucose (FEG) by up to 50% under hyperglycemic conditions. By fitting the titration curve using a newly introduced method that avoids variability in estimating the threshold of renal glucose excretion, we found that tofogliflozin and phlorizin lowered the threshold and extended the splay in a dose-dependent manner without significantly affecting the tubular transport maximum for glucose (TmG). Our results demonstrate the contribution of SGLT2 to renal glucose reabsorption (RGR) in cynomolgus monkeys and demonstrate that competitive inhibition of cSGLT2 exerts a glucosuric effect by mainly extending splay and lowering threshold without affecting TmG.
Asunto(s)
Compuestos de Bencidrilo/farmacología , Glucosa/metabolismo , Glucósidos/farmacología , Macaca fascicularis/orina , Florizina/farmacología , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Transportador 2 de Sodio-Glucosa/efectos de los fármacos , Animales , Células COS/metabolismo , Células COS/patología , Chlorocebus aethiops , ADN Complementario/genética , Relación Dosis-Respuesta a Droga , Técnicas In Vitro , Riñón/metabolismo , Riñón/patología , Masculino , Metilglucósidos/metabolismo , Modelos Animales , Transportador 1 de Sodio-Glucosa/antagonistas & inhibidores , Transportador 1 de Sodio-Glucosa/efectos de los fármacos , Transportador 1 de Sodio-Glucosa/genética , Transportador 2 de Sodio-Glucosa/genéticaRESUMEN
1. Tofogliflozin is a novel and selective SGLT2 inhibitor increasing glucosuria by inhibition of glucose re-absorption in the kidney for the treatment of type 2 diabetes mellitus. 2. In this study, the metabolism and the mass balance of tofogliflozin was evaluated following administration of a single oral dose of 20 mg [(14)C]-tofogliflozin to six healthy subjects. 3. Tofogliflozin underwent mainly oxidative metabolism in the ethylphenyl moiety, but also minor glucuronide conjugates of metabolites and the parent drug were formed. 4. In plasma, the parent drug and its major phenyl acetic acid metabolite M1 accounted for 42% and 52% of the total drug-related material, respectively. The hydroxyl metabolites and their successor ketone metabolite showed an exposure well below 5%, along with an acyl glucuronide of M1. 5. Tofogliflozin was completely absorbed with subsequent predominate metabolic clearance and a small contribution of direct urinary elimination. Approximately, 76% of the dose was excreted in urine and 20% in faeces within 72 h. The high absorption of tofogliflozin was exemplified by the small trace of parent drug in faeces. The phenyl acetic acid metabolite M1 was the major component excreted in urine and faeces accounting for more than half of the dose. Tofogliflozin demonstrated a high metabolic turnover.
Asunto(s)
Compuestos de Bencidrilo/administración & dosificación , Compuestos de Bencidrilo/farmacocinética , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Glucósidos/administración & dosificación , Glucósidos/farmacocinética , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Absorción , Administración Oral , Área Bajo la Curva , Glucemia/análisis , Heces , Glucosa/química , Glucurónidos/química , Voluntarios Sanos , Humanos , Masculino , Estrés Oxidativo , Transportador 2 de Sodio-GlucosaRESUMEN
To understand the risk of hypoglycemia associated with urinary glucose excretion (UGE) induced by sodium-glucose cotransporter (SGLT) inhibitors, it is necessary to know the relationship between the ratio of contribution of SGLT2 vs. SGLT1 to renal glucose reabsorption (RGR) and the glycemic levels in vivo. To examine the contributions of SGLT2 and SGLT1 in normal rats, we compared the RGR inhibition by tofogliflozin, a highly specific SGLT2 inhibitor, and phlorizin, an SGLT1 and SGLT2 (SGLT1/2) inhibitor, at plasma concentrations sufficient to completely inhibit rat SGLT2 (rSGLT2) while inhibiting rSGLT1 to different degrees. Under hyperglycemic conditions by glucose titration, tofogliflozin and phlorizin achieved ≥50% inhibition of RGR. Under hypoglycemic conditions by hyperinsulinemic clamp, RGR was reduced by 20-50% with phlorizin and by 1-5% with tofogliflozin, suggesting the smaller contribution of rSGLT2 to RGR under hypoglycemic conditions than under hyperglycemic conditions. Next, to evaluate the hypoglycemic potentials of SGLT1/2 inhibition, we measured the plasma glucose (PG) and endogenous glucose production (EGP) simultaneously after UGE induction by SGLT inhibitors. Tofogliflozin (400 ng/ml) induced UGE of about 2 mg·kg⻹·min⻹ and increased EGP by 1-2 mg·kg⻹·min⻹, resulting in PG in the normal range. Phlorizin (1,333 ng/ml) induced UGE of about 6 mg·kg⻹·min⻹ and increased EGP by about 4 mg·kg⻹·min⻹; this was more than with tofogliflozin, but the minimum PG was lower. These results suggest that the contribution of SGLT1 to RGR is greater under lower glycemic conditions than under hyperglycemic conditions and that SGLT2-selective inhibitors pose a lower risk of hypoglycemia than SGLT1/2 inhibitors.
Asunto(s)
Compuestos de Bencidrilo/efectos adversos , Glucósidos/efectos adversos , Glucosuria/inducido químicamente , Hipoglucemiantes/efectos adversos , Riñón/efectos de los fármacos , Bloqueadores de los Canales de Sodio/efectos adversos , Transportador 1 de Sodio-Glucosa/antagonistas & inhibidores , Inhibidores del Cotransportador de Sodio-Glucosa 2 , Absorción/efectos de los fármacos , Animales , Compuestos de Bencidrilo/administración & dosificación , Compuestos de Bencidrilo/farmacocinética , Compuestos de Bencidrilo/uso terapéutico , Glucemia/análisis , Creatinina/metabolismo , Creatinina/orina , Relación Dosis-Respuesta a Droga , Gluconeogénesis/efectos de los fármacos , Glucósidos/administración & dosificación , Glucósidos/farmacocinética , Glucósidos/uso terapéutico , Glucosuria/etiología , Hiperglucemia/sangre , Hiperglucemia/tratamiento farmacológico , Hiperglucemia/metabolismo , Hiperglucemia/orina , Hipoglucemia/sangre , Hipoglucemia/inducido químicamente , Hipoglucemia/metabolismo , Hipoglucemia/orina , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/uso terapéutico , Riñón/metabolismo , Masculino , Florizina/administración & dosificación , Florizina/efectos adversos , Florizina/farmacocinética , Florizina/uso terapéutico , Ratas , Ratas Wistar , Bloqueadores de los Canales de Sodio/administración & dosificación , Bloqueadores de los Canales de Sodio/farmacocinética , Bloqueadores de los Canales de Sodio/uso terapéutico , Transportador 1 de Sodio-Glucosa/metabolismo , Transportador 2 de Sodio-Glucosa/metabolismoRESUMEN
We previously reported that monoclonal antibodies (mAbs) with a high isoelectric point (pI) value tended to exhibit fast plasma clearance (CL) and large steady-state volume of distribution (Vdss) in mice. However, the positive correlation between pI, CL, and Vdss cannot be described by the reported physiologically based pharmacokinetic (PBPK) models, in which FcRn-mediated transcytosis of mAbs is set to be minimal compared to convection-mediated transport. To address this issue, physiological parameters (lymph flow rate, reflection coefficient, endothelial uptake clearance, and FcRn concentration) were optimized based on the pharmacokinetic profiles of mAbs with various pI values in wild type and FcRn-deficient (beta-2-microglobulin knockout [KO]) mice. Simulations using the PBPK model developed in this study showed a positive correlation between pI, CL and Vdss observed in wild-type mice. Therefore, this model successfully characterized our hypothetical mechanism that an electrostatic positive interaction between mAbs and the endothelial membrane enhances FcRn-mediated transcytosis of mAbs, resulting in large Vdss. We sought to determine the right contribution of the two pathways of antibody distribution to the interstitial space and established a new model that could effectively capture the effect of pI on FcRn-mediated distribution of mAbs in the body.